IFNA1 and melanoma: We show that they are non-coding mutations affecting ETS transcription factor binding sites and gene-promoter activity, leading to decreased expression rather than the miRNA-mediated increased expression proposed by Gartner et al.10Although we were unable to validate the impact of the mutations on IFN signaling in our Mel-ST cell model, our data suggest a negative effect on immunotherapy response in individuals with melanoma.